Steve Love
About Steve Love
Independent director of OmniAb, Inc. since 2023; age 56. Currently CFO of Sift Science, Inc. (since April 2024). Former CFO roles at Heap (2021–Dec 2023), Juniper Square (2020–2021), and Dialpad (since 2016). Education: B.S. and MAcc, University of Southern California; Certified Public Accountant (CA, inactive). Chairs both the Audit Committee (audit committee financial expert) and the Human Capital Management & Compensation Committee; Board has determined he is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sift Science, Inc. | Chief Financial Officer | Apr 2024–present | Finance leadership at AI identity-centric fraud prevention platform |
| Heap Inc. (acquired by Contentsquare) | Chief Financial Officer | Sep 2021–Dec 2023 | Finance leadership during sale to Contentsquare in Dec 2023 |
| Juniper Square Inc. | Chief Financial Officer | 2020–2021 | Finance leadership |
| Dialpad, Inc. | Chief Financial Officer | Since 2016 (prior role) | Finance leadership |
| Mblox Inc. (acquired by CLX) | Senior finance leadership | Prior to 2016 | Led growth; company sold in Jul 2016 |
| Evolv Inc. (acquired by Cornerstone OnDemand) | Senior finance leadership | Prior to Nov 2014 | Led growth; company sold in Nov 2014 |
| Affymax, Inc.; Connetics Corporation | Finance leadership | Earlier career | Biotech/software finance leadership |
| Ernst & Young LLP | Auditor | Career start | Supported private/public biotech and software companies |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Sift Science, Inc. | Chief Financial Officer | Apr 2024–present | Operating role; not a public company directorship |
No other public company board roles are disclosed for Mr. Love in OmniAb’s director biographies section .
Board Governance
| Item | Detail |
|---|---|
| Independence | Independent director under Nasdaq rules |
| Board leadership | Board Chair: John Higgins (separate from CEO) |
| Committees | Audit Committee (Chair); Human Capital Management & Compensation Committee (Chair) |
| Financial expert | Designated “audit committee financial expert” by Board |
| Attendance | All incumbent directors attended at least 75% of Board/committee meetings in 2024 |
| Insider trading/hedging | Company policy prohibits pledging, hedging, margin, short sales, and derivatives in company stock |
| Ownership guidelines | Directors must own ≥3x annual retainer within 5 years; Mr. Love has until Nov 2028 to comply |
Board and committee meetings (2024):
- Board: 2 in-person; 3 virtual
- Audit: 1 in-person; 3 virtual
- HCMCC: 0 in-person; 4 virtual
- NCG: 0 in-person; 2 virtual
- Science & Tech: 0 in-person; 3 virtual
Fixed Compensation
| Component | 2024 Policy/Amount | Source |
|---|---|---|
| Annual Board retainer (non-employee director) | $50,000 | |
| Audit Committee – Chair retainer | $20,000 | |
| HCM & Compensation Committee – Chair retainer | $15,000 | |
| Meeting fees | None | |
| Election to receive retainers | Cash or vested common stock permissible |
| 2024 Actual (Mr. Love) | Amount (USD) |
|---|---|
| Fees Paid in Cash | $70,971 |
Note: Variance versus sum of chair/base retainers may reflect proration or election to receive retainers in equity per policy .
Performance Compensation
| Equity Element | 2024 Policy Details | Mr. Love 2024 Reported (Fair Value or Count) |
|---|---|---|
| Annual director grant | 20,000 RSUs + 40,000 options; vests in full by next annual meeting or first anniversary; change-in-control full vesting | RSU awards $83,800; Option awards $93,588 (grant date fair values) |
| Initial director grant (if new) | 40,000 RSUs + 80,000 options; vests over 3 years | Not applicable in 2024 (appointed 2023) |
As of 12/31/2024, outstanding director awards:
- RSUs: 46,667; Options: 120,000 (for Mr. Love)
Clawback policy (scope): Recovery of certain erroneously paid incentive compensation received by Section 16 officers on/after Oct 2, 2023 if an accounting restatement is required; administered by HCMCC .
Other Directorships & Interlocks
| Company/Institution | Role | Interlock/Relationship |
|---|---|---|
| Connetics Corporation | Mr. Love held finance leadership earlier in career | Board Chair John Higgins previously CFO/EVP at Connetics (1997–2006), indicating a historical professional overlap between two current directors |
No related-party transactions involving Mr. Love are disclosed in the “Certain Relationships and Related Party Transactions” section; disclosed related-party transaction in 2024 involved Photinia and another director (Dr. Cochran) .
Expertise & Qualifications
- Finance and accounting expertise; CPA (California, inactive) .
- Designated audit committee financial expert by the Board .
- Extensive SaaS and biotech finance leadership; M&A integration experience (Evolv, Mblox exits) .
Equity Ownership
| Item | Detail |
|---|---|
| Total beneficial ownership (Apr 23, 2025) | 99,999 shares; <1% of outstanding |
| Breakdown (as of Apr 23, 2025) | 13,333 common; 66,666 options exercisable within 60 days; 20,000 RSUs vesting within 60 days |
| Shares outstanding (for % calc context) | 122,335,336 (includes 16,292,542 earnout shares subject to forfeiture) |
| Pledging/Hedging | Prohibited by company policy |
| Ownership guidelines | ≥3x annual retainer within 5 years; Mr. Love deadline Nov 2028 |
Recent Form 4 activity (illustrative, most recent):
| Filing/Txn Date | Type | Security | Qty | Price | Post-Txn Ownership | Source |
|---|---|---|---|---|---|---|
| 2025-11-03 (txn 2025-11-01) | M-Exempt | Common Stock | 13,333 | $0.00 | 71,666 common | https://www.sec.gov/Archives/edgar/data/1846253/000162828025048221/0001628280-25-048221-index.htm |
| 2025-11-03 (txn 2025-11-01) | M-Exempt (settlement) | Restricted Stock Units | 13,333 | $0.00 | 33,334 RSUs | https://www.sec.gov/Archives/edgar/data/1846253/000162828025048221/0001628280-25-048221-index.htm |
Governance Assessment
-
Strengths:
- Independent director; chairs both Audit and HCMCC; designated audit committee financial expert—strong financial oversight credentials .
- Director stock ownership guideline in place with clear compliance timeline; hedging/pledging prohibited—alignment and risk control mechanisms .
- Director pay includes meaningful equity (RSUs/options), reinforcing alignment with shareholders .
-
Watch items:
- Concentration of committee leadership (simultaneously chairing Audit and HCMCC) can elevate workload/oversight concentration risk; continued monitoring of meeting attendance and committee effectiveness is warranted. 2024 disclosure indicates all directors met ≥75% attendance and committees met regularly .
- No related-party transactions disclosed involving Mr. Love; continue to monitor for any future operating ties given extensive SaaS/biotech network .
Supporting references:
- Director biography, independence, roles: ; Committee charters and financial expert designation: .
- Meeting frequencies and attendance: .
- Director compensation policy and 2024 actuals: .
- Beneficial ownership and breakdown: ; Outstanding shares context: .
- Insider trading policy (hedging/pledging): .
- Related-party transactions section (no Love transactions disclosed): .
- Form 4 transactions (SEC EDGAR URLs provided above).